Mesa Laboratories, Inc. (NASDAQ:MLAB) Stock Holdings Lessened by Stifel Financial Corp

Stifel Financial Corp trimmed its stake in Mesa Laboratories, Inc. (NASDAQ:MLAB) by 1.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,882 shares of the medical instruments supplier’s stock after selling 68 shares during the quarter. Stifel Financial Corp’s holdings in Mesa Laboratories were worth $1,113,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Veriti Management LLC purchased a new stake in shares of Mesa Laboratories in the fourth quarter worth approximately $44,000. Captrust Financial Advisors lifted its position in shares of Mesa Laboratories by 27.6% in the third quarter. Captrust Financial Advisors now owns 434 shares of the medical instruments supplier’s stock worth $112,000 after purchasing an additional 94 shares in the last quarter. Nisa Investment Advisors LLC lifted its position in shares of Mesa Laboratories by 600.0% in the fourth quarter. Nisa Investment Advisors LLC now owns 525 shares of the medical instruments supplier’s stock worth $150,000 after purchasing an additional 450 shares in the last quarter. Cresset Asset Management LLC purchased a new stake in shares of Mesa Laboratories in the fourth quarter worth approximately $215,000. Finally, Amalgamated Bank purchased a new stake in shares of Mesa Laboratories in the fourth quarter worth approximately $224,000. 93.54% of the stock is owned by institutional investors and hedge funds.

In other Mesa Laboratories news, Director John Bradley Schmieder sold 477 shares of the stock in a transaction that occurred on Tuesday, January 12th. The stock was sold at an average price of $285.23, for a total transaction of $136,054.71. Following the transaction, the director now owns 73,467 shares in the company, valued at $20,954,992.41. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Brian David Archbold sold 223 shares of the stock in a transaction that occurred on Wednesday, March 10th. The shares were sold at an average price of $271.78, for a total value of $60,606.94. Following the transaction, the senior vice president now owns 377 shares in the company, valued at approximately $102,461.06. The disclosure for this sale can be found here. Insiders sold 8,670 shares of company stock worth $2,352,082 in the last 90 days. 6.10% of the stock is currently owned by corporate insiders.

NASDAQ:MLAB opened at $238.00 on Thursday. The stock’s 50 day moving average price is $261.82 and its 200 day moving average price is $272.90. Mesa Laboratories, Inc. has a 52 week low of $204.50 and a 52 week high of $307.97. The company has a market capitalization of $1.22 billion, a P/E ratio of -340.00 and a beta of 0.39. The company has a debt-to-equity ratio of 0.36, a quick ratio of 13.74 and a current ratio of 14.34.

Mesa Laboratories (NASDAQ:MLAB) last released its quarterly earnings data on Wednesday, February 3rd. The medical instruments supplier reported $0.76 EPS for the quarter, missing analysts’ consensus estimates of $1.27 by ($0.51). Mesa Laboratories had a positive return on equity of 6.39% and a negative net margin of 2.04%. The firm had revenue of $34.17 million during the quarter, compared to analyst estimates of $32.30 million. As a group, sell-side analysts forecast that Mesa Laboratories, Inc. will post 5.84 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 15th. Investors of record on Monday, May 31st will be issued a $0.16 dividend. The ex-dividend date is Thursday, May 27th. This represents a $0.64 dividend on an annualized basis and a yield of 0.27%. Mesa Laboratories’s dividend payout ratio is currently 15.20%.

Separately, Zacks Investment Research lowered shares of Mesa Laboratories from a “hold” rating to a “sell” rating in a research report on Wednesday, February 10th.

Mesa Laboratories Profile

Mesa Laboratories, Inc designs, manufactures, and markets quality control instruments and disposable products in the United States, Canada, Europe, and Japan. The company's Sterilization and Disinfection Control segment manufactures and markets biological indicators comprising spore strips, self-contained products, and culture media, as well as process challenge devices; and offers testing services.

See Also: What is the definition of arbitrage?

Want to see what other hedge funds are holding MLAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mesa Laboratories, Inc. (NASDAQ:MLAB).

Institutional Ownership by Quarter for Mesa Laboratories (NASDAQ:MLAB)

Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.